A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

HS Walter; SA Rule; MJS Dyer; L Karlin; C Jones; B Cazin; P Quittet; N Shah; CV Hutchinson; H Honda; K Duffy; J Birkett; V Jamieson; N Courtenay-Luck; T Yoshizawa; J Sharpe; T Ohno; S Abe; A Nishimura; G Cartron; F Morschhauser; C Fegan; G Salles

doi:10.1182/blood-2015-08-664086

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

HS Walter, SA Rule, MJS Dyer, L Karlin, C Jones, B Cazin, P Quittet, N Shah, CV Hutchinson, H Honda, K Duffy, J Birkett, V Jamieson, N Courtenay-Luck, T Yoshizawa, J Sharpe, T Ohno, S Abe, A Nishimura, G CartronF Morschhauser, C Fegan, G Salles

Peninsula Medical School

Research output: Contribution to journal › Article › peer-review

Abstract

Key Points We report a first-in-human dose-escalation study in relapsed/refractory B-cell malignancies with the potent BTK inhibitor ONO/GS-4059. ONO/GS-4059 induced clinically durable responses in relapsed/refractory B-cell malignancies without significant toxicities.

Original language	English
Pages (from-to)	411-419
Number of pages	0
Journal	Blood
Volume	127
Issue number	4
DOIs	https://doi.org/10.1182/blood-2015-08-664086
Publication status	Published - 28 Jan 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1182/blood-2015-08-664086

Cite this

Walter, HS., Rule, SA., Dyer, MJS., Karlin, L., Jones, C., Cazin, B., Quittet, P., Shah, N., Hutchinson, CV., Honda, H., Duffy, K., Birkett, J., Jamieson, V., Courtenay-Luck, N., Yoshizawa, T., Sharpe, J., Ohno, T., Abe, S., Nishimura, A., ... Salles, G. (2016). A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood, 127(4), 411-419. https://doi.org/10.1182/blood-2015-08-664086

@article{5c76e193c6bd457f8e3698c6039c191a,

title = "A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies",

abstract = "Key Points We report a first-in-human dose-escalation study in relapsed/refractory B-cell malignancies with the potent BTK inhibitor ONO/GS-4059. ONO/GS-4059 induced clinically durable responses in relapsed/refractory B-cell malignancies without significant toxicities.",

author = "HS Walter and SA Rule and MJS Dyer and L Karlin and C Jones and B Cazin and P Quittet and N Shah and CV Hutchinson and H Honda and K Duffy and J Birkett and V Jamieson and N Courtenay-Luck and T Yoshizawa and J Sharpe and T Ohno and S Abe and A Nishimura and G Cartron and F Morschhauser and C Fegan and G Salles",

year = "2016",

month = jan,

day = "28",

doi = "10.1182/blood-2015-08-664086",

language = "English",

volume = "127",

pages = "411--419",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier B.V.",

number = "4",

}

Walter, HS, Rule, SA, Dyer, MJS, Karlin, L, Jones, C, Cazin, B, Quittet, P, Shah, N, Hutchinson, CV, Honda, H, Duffy, K, Birkett, J, Jamieson, V, Courtenay-Luck, N, Yoshizawa, T, Sharpe, J, Ohno, T, Abe, S, Nishimura, A, Cartron, G, Morschhauser, F, Fegan, C & Salles, G 2016, 'A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies', Blood, vol. 127, no. 4, pp. 411-419. https://doi.org/10.1182/blood-2015-08-664086

TY - JOUR

T1 - A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

AU - Walter, HS

AU - Rule, SA

AU - Dyer, MJS

AU - Karlin, L

AU - Jones, C

AU - Cazin, B

AU - Quittet, P

AU - Shah, N

AU - Hutchinson, CV

AU - Honda, H

AU - Duffy, K

AU - Birkett, J

AU - Jamieson, V

AU - Courtenay-Luck, N

AU - Yoshizawa, T

AU - Sharpe, J

AU - Ohno, T

AU - Abe, S

AU - Nishimura, A

AU - Cartron, G

AU - Morschhauser, F

AU - Fegan, C

AU - Salles, G

PY - 2016/1/28

Y1 - 2016/1/28

N2 - Key Points We report a first-in-human dose-escalation study in relapsed/refractory B-cell malignancies with the potent BTK inhibitor ONO/GS-4059. ONO/GS-4059 induced clinically durable responses in relapsed/refractory B-cell malignancies without significant toxicities.

AB - Key Points We report a first-in-human dose-escalation study in relapsed/refractory B-cell malignancies with the potent BTK inhibitor ONO/GS-4059. ONO/GS-4059 induced clinically durable responses in relapsed/refractory B-cell malignancies without significant toxicities.

U2 - 10.1182/blood-2015-08-664086

DO - 10.1182/blood-2015-08-664086

M3 - Article

SN - 0006-4971

VL - 127

SP - 411

EP - 419

JO - Blood

JF - Blood

IS - 4

ER -

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this